CLINICAL_TRIALS
trial_result
· 2018-10-19
Clinical Trial Update: A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia [Phase 3]
Summary
Phase III trial of SM-13496 (lurasidone HCl) in schizophrenia has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sumitomo Pharma Co., Ltd. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2018-10-19